APRE - Aprea Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5734.67M
Enterprise Value 3830.07M
Trailing P/E N/A
Forward P/E 1-17.33
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-36.97

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3∞%
S&P500 52-Week Change 315.46%
52 Week High 353.11
52 Week Low 315.10
50-Day Moving Average 337.74
200-Day Moving Average 331.39

Share Statistics

Avg Vol (3 month) 3117.41k
Avg Vol (10 day) 369.36k
Shares Outstanding 520.99M
Float 10.36M
% Held by Insiders 15.35%
% Held by Institutions 186.62%
Shares Short (Jan 30, 2020) 4283.51k
Short Ratio (Jan 30, 2020) 43.27
Short % of Float (Jan 30, 2020) 42.75%
Short % of Shares Outstanding (Jan 30, 2020) 41.35%
Shares Short (prior month Dec 30, 2019) 4223.15k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -22.45M
Net Income Avi to Common (ttm)-19.67M
Diluted EPS (ttm)-26.67
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)52.33M
Total Cash Per Share (mrq)2.49
Total Debt (mrq)585.26k
Total Debt/Equity (mrq)1.24
Current Ratio (mrq)5.92
Book Value Per Share (mrq)-59.91

Cash Flow Statement

Operating Cash Flow (ttm)-20.06M
Levered Free Cash Flow (ttm)N/A